Abstract
Neuromyelitis optica is a severe autoimmune condition affecting the central nervous system characterized by a relapsing disease course. Rituximab is a chimeric monoclonal antibody against the protein CD20, and is one of the most utilized medications for management of this disease. A known complication of rituximab use is neutropenia. We report on two patients who developed symptomatic early-onset rituximab-induced agranulocytosis who safely received granulocyte colony-stimulating factor. Neutrophil counts recovered quickly and both patients continue to receive rituximab without further incident.
Original language | English (US) |
---|---|
Pages (from-to) | 29-30 |
Number of pages | 2 |
Journal | Journal of Neuroimmunology |
Volume | 287 |
DOIs | |
State | Published - Oct 15 2015 |
Keywords
- Agranulocytosis
- G-CSF
- NMO
- Neuromyelitis optica
- Neutropenia
- Rituximab
ASJC Scopus subject areas
- Immunology and Allergy
- Immunology
- Neurology
- Clinical Neurology